Acquisition to boost Janison’s earnings by 70%

|

Published 28-MAR-2019 09:59 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The timing of an announcement this week regarding an important acquisition by Janison Education Group Ltd (ASX:JAN) couldn’t have been worse.

Both global and Australian equities markets went into freefall on the day the group informed the market that it had entered into a binding agreement to acquire LTC Holdco Pty Ltd (LTC), the parent company of Language & Testing Consultants Pty Ltd.

JAN is an integrated learning business that is used by large enterprises and government departments to build capability in their workforce, indicating that the company benefits by being leveraged to relatively essential spending.

The group also provides a leading global platform for the provision of digital exam authoring, testing and marking which is sold to national education departments, tertiary institutions and independent educational institutions.

LTC will be a good fit with the business as it is a market-leading examination services business headquartered in Sydney with operations both domestically and, increasingly, internationally.

The company facilitates outsourced end-to-end exam management services on behalf of large universities, colleges and professional certification bodies.

Acquisition represents a bargain

The cash and scrip acquisition will be immediately earnings per share accretive, and it will have a significant impact on earnings in fiscal 2020.

Such is the earnings boost provided by the acquisition that it prompted Bell Potter analyst Alex Mclean to upgrade his underlying EBITDA forecasts for 2020 by 71%.

This would be the first full year contribution by LTC, and in increasing his forecasts from $3.9 million to $6.7 million, it has made fiscal 2020 a transformational year for the group.

In terms of the bottom line, it will increase more than three-fold and earnings per share will nearly treble to 2.3 cents taking into account the increased shares on issue from the $6 million equity raising that the company has undertaken in conjunction with the acquisition.

Upgrades to earnings and price target

Mclean views the acquisition as extremely good value, noting that it is paying approximately five times fiscal 2018 EBITDA, while Janison’s underlying earnings multiple for fiscal 2020 prior to the transaction was 14.

Taking into account the upgraded earnings impact and the strategic advantages of the acquisition, he has increased his earnings per share estimates for fiscal years 2019, 2020 and 2021 by 52%, 43% and 22% respectively.

This has prompted him to increase his 12 month share price target from 50 cents to 60 cents, implying upside of approximately 60% to Wednesday’s closing price of 38 cents.

While the downturn in equities markets arguably overshadowed this promising development, it would appear that Janison’s financial metrics will do the talking in the near to medium-term, providing share price momentum commensurate with its substantially upgraded earnings profile.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X